From a $5 billion program in 2014 to a $30 billion program in 2019, 340B saw a 47% compound annual growth rate in five years, significantly outpacing other government pricing programs. Current estimates place it at about $34 billion today.
The Road To 340B Was Paved With Good Intentions So Why Are Drug Companies Looking For An Off Ramp?
